October 4, 2022

Medical Trend

Medical News and Medical Resources

Celarevir potassium with sofosbuvir treats chronic hepatitis C infection

Celarevir potassium with sofosbuvir treats chronic hepatitis C infection

 

Celarevir potassium with sofosbuvir treats chronic hepatitis C infection.   J Gastroenterol Hepatol: The effectiveness and safety of celarevir potassium tablets combined with sofosbuvir tablets in the treatment of chronic hepatitis C virus infection.


Most of the adverse events that occurred in the study were mild or moderate, and they were cured or relieved without clinical intervention.

Celarevir potassium with sofosbuvir treats chronic hepatitis C infection 

 

This study is a multi-center, single-arm, open phase III clinical trial. To evaluate the efficacy and safety of HCV nonstructural protein 3/4A inhibitor celarevir potassium tablets combined with sofosbuvir tablets in Chinese patients with chronic hepatitis C and non-cirrhosis.

Cerarevir potassium tablets, 100 mg, 2 times a day; Sofosbuvir, 400 mg, once a day, combined administration for 12 or 24 weeks for the treatment of chronic Chinese patients with non-cirrhosis, initial treatment or interferon treatment Patients with hepatitis C. The primary endpoint is the sustained virological response (SVR12) rate at 12 weeks after discontinuation.

The researchers successfully enrolled 205 subjects in 23 clinical research centers across the country, of which 202 subjects completed the study and 3 subjects withdrew early.

Of the 205 subjects, 27 (13.2%) were interferon-treated patients, and all subjects had HCV genotype 1.

The sustained virological response rate at 12 weeks after discontinuation was 98% (201/205) (95% confidence interval: 95.1%~99.5%), of which the HCV gene 1a subgroup was 100%, and the gene 1b subgroup It is 98.0%.

In another exploratory study, 21 subjects with HCV genotype 2, 7 subjects with genotype 3, and 8 subjects with genotype 6 were enrolled. The continuous virological response at 12 weeks after drug withdrawal The rate is 100%.

Most of the adverse events that occurred in the study were mild or moderate, and they were cured or relieved without clinical intervention.

Celarevir potassium with sofosbuvir treats chronic hepatitis C infection

Studies have shown that celarevir potassium tablets combined with sofosbuvir tablets is a full oral treatment without ribavirin, which is good for patients with chronic hepatitis C who are not cirrhotic, newly treated or treated with interferon Efficacy and safety.

 

 

 

 

(source:internet, reference only)


Disclaimer of medicaltrend.org